GWP
NVCR icon

Gen-Wealth Partners’s NovoCure NVCR Stock Holding History

Gen-Wealth Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$207 Hold
19
– – ﹤0.01% 713
2025
Q4 		$246 Hold
19
– – ﹤0.01% 675
2025
Q3 		$245 Hold
19
– – ﹤0.01% 672
2025
Q2 		$338 Hold
19
– – ﹤0.01% 623
2025
Q1 		$339 Hold
19
– – ﹤0.01% 593
2024
Q4 		$566 Hold
19
– – ﹤0.01% 617
2024
Q3 		$323 Hold
19
– – ﹤0.01% 641
2024
Q2 		$325 Hold
19
– – ﹤0.01% 627
2024
Q1 		$297 Buy
+19
New +$279 ﹤0.01% 615

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Gen-Wealth Partners's NVCR Position: Q1 2026 in Review

Gen-Wealth Partners held its NovoCure (NVCR) position steady in Q1 2026 at 19 shares worth $207. The position accounts for ﹤0.01% of the portfolio, ranked #713.

Gen-Wealth Partners first reported a position in NVCR in Q1 2024 and has held it in 9 quarters since. The position peaked at $566 in Q4 2024. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Gen-Wealth Partners held 19 shares of NovoCure worth $207 as of Q1 2026.
  • Gen-Wealth Partners left its NovoCure share count unchanged in Q1 2026.
  • NovoCure made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q1 2026, its #713 holding.
  • Gen-Wealth Partners first reported a position in NovoCure in Q1 2024 and has held it in 9 quarters since.
  • Gen-Wealth Partners's NovoCure position peaked at $566 in Q4 2024.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Gen-Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.